BERKELEY, CA (UroToday.com) - Our chapter on BPH in the... (Source: UroToday)MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Treatment with tadalafil for lower urinary tract symptoms in men with benign prostatic hyperplasia does not impair their bladder function, researchers report in the March issue of the Journal of Urology. Reuters Health Information (Source: Medscape Medical News Headlines)

Conclusions. Alfuzosin 10 mg OD administered for 6 months provides a marked and rapid (within 1 week) improvement in LUTS and bother score while improving both ED and EjD. Leungwattanakij S, Watanachote D, Noppakulsatit P, Petchpaibuol T, Choeypunt N, Tongbai T, Wanamkang T, Lojanapiwat B, Permpongkosol S, Tantiwong A, Pripatnanont C, Akarasakul D, Kongwiwatanakul S, and Chotikawanich E. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. J Sex Med **;**:**[ndash]**. (Source: The Journal of Sexual Medicine)

SAN FRANCISCO (MedPage Today) -- For men with benign prostatic hyperplasia (BPH), dutasteride (Avodart) both prevents prostate cancer and boosts the predictive power of prostate specific antigen (PSA), researchers affirmed. (Source: MedPage Today Hematology/Oncology)

Prostate cancer TURP procedure. You may be familiar with the TURP (transurethral resection of the prostate) procedure commonly used to treat benign prostatic hyperplasia (BPH), but did you know that it can also be used in men with prostate cancer. (Source: About.com Prostate Cancer)

Systemic inflammation might increase the risk of benign prostatic hyperplasia (BPH), researchers report in a February 8th online paper in the American Journal of Epidemiology. Reuters Health Information (Source: Medscape Urology Headlines)MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

WASHINGINTON (MedPage Today) -- The FDA approved the first generic version of the benign prostatic hyperplasia (BPH) medication tamsulosin (Flomax). (Source: MedPage Today Product Alert)

The U.S. Food and Drug Administration approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate gland causes problems with urination... (Source: Prostate News From Medical News Today)

The U.S. Food and Drug Administration approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate gland causes problems with urination. The most common symptoms of BPH include a weak stream during urination, urgency, leaking or dribbling, as well as more frequent urination, especially at night. BPH is common among older men... (Source: Health News from Medical News Today)

The U.S. Food and Drug Administration today approved the first generic version of Flomax Capsules 0.4 mg (tamsulosin hydrochloride) to treat benign prostatic hyperplasia (BPH), a condition in which an enlarged prostate gland causes problems with urination. (Source: Food and Drug Administration)

Photoselective vaporization of prostate tissue can improve storage and voiding symptoms for 12 months or more in men with benign prostatic hyperplasia (BPH), Italian researchers report. Reuters Health Information (Source: Medscape Urology Headlines)MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

(Source: Modern Medicine)

(Source: Modern Medicine)

(Source: Modern Medicine)

(Source: Modern Medicine)

For benign prostatic hyperplasia (BPH), transurethral resection of the prostate (TURP), contact laser prostatectomy, and electrovaporization of the prostate provide similar improvements in symptoms and quality of life, long-term data suggest. Reuters Health Information (Source: Medscape Today Headlines)

Suprapubic prostatectomy is the tested and most widely accepted option of surgery for men with large-volume benign prostate hyperplasia (BPH) and against which newer alternatives need to be compared. The morbidity and mortality associated with open suprapubic prostatectomy has generally decreased over the years, yet morbid events are still commonly reportedly. Significant and often excessive hemorrhage is the most immediate and serious problem of suprapubic prostatectomy. With regard to surgical technique, our study suggests that tapering the bladder neck to index finger size and oversewing of the mucosal edge may be important for hemostasis. Ensuring adequate hemostatic control lowers morbidity and reduces the need for blood transfusion. Blood transfusion in general is highly undesirable ...

CONCLUSION: The results of our current survey provide useful insight into variations in the clinical practice of Korean urologists. They also indicate the need to develop further practical guidelines based on solid clinical data and to ensure that these guidelines are widely promoted and accepted by the urological community. PMID: 20191018 [PubMed - in process] (Source: Yonsei Medical Journal)

Study Type [ndash] Therapy (RCT)Level of Evidence 1b To compare long-term results of transurethral resection of the prostate (TURP), contact laser prostatectomy (CLP) and electrovaporization of the prostate (EVAP) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Between 1996 and 2001, a prospective, randomized controlled trial was conducted in 150 men with LUTS suggestive of BPH, who had a prostate volume of 20[ndash]65 mL and a Schäfer's obstruction grade of [ge]2. Outcome variables were the International Prostate Symptom Score (IPSS), Quality of Life (QoL) question, Symptom Problem Index (SPI), BPH Impact Index (BII), maximum urinary flow rate (Qmax), prostate volume, prostate specific antigen (PSA) level, morbidity and mortality. In 2008...MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Study Type [ndash] Therapy (RCT)Level of Evidence 1b To evaluate the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in men with and without erectile dysfunction (ED). This was a multicentre, double-blind, placebo- and active-controlled, parallel-group study conducted across 45 centres in North and South America, Europe, and Australia. In all, 418 men aged [ge]40 years with a clinical diagnosis of BPH, an International Prostate Symptom Score (IPSS) of [ge]13, and maximum urinary flow rate (Qmax) of 5[ndash]15 mL/s for a voided volume of >150 mL were stratified into two groups (with and without ED) and randomized to one of seven treatment groups, i.e. UK-369,0...